Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome

Singh, Satnam, Beadle, Roger, Cameron, Donnie ORCID: https://orcid.org/0000-0001-9841-6909, Rudd, Amelia, Bruce, Maggie, Jagpal, Baljit, Schwarz, Konstantin, Brindley, Gemma, Mckiddie, Fergus, Nightingale, Peter, Lang, Chim, Dawson, Dana and Frenneaux, Michael (2014) Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. Future Cardiology, 10 (6). pp. 693-698. ISSN 1479-6678

Full text not available from this repository. (Request a copy)

Abstract

Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.

Item Type:	Article
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health Faculty of Medicine and Health Sciences > Research Centres > Population Health
Depositing User:	Pure Connector
Date Deposited:	09 Mar 2015 07:29
Last Modified:	19 Oct 2023 01:26
URI:	https://ueaeprints.uea.ac.uk/id/eprint/52435
DOI:	10.2217/fca.14.62

Actions (login required)

View Item